Cargando…
The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537685/ https://www.ncbi.nlm.nih.gov/pubmed/33061825 http://dx.doi.org/10.1155/2020/3203241 |
_version_ | 1783590714519584768 |
---|---|
author | Conticini, Edoardo Sota, Jurgen Falsetti, Paolo Baldi, Caterina Bardelli, Marco Bellisai, Francesca Tosi, Gian Marco Frediani, Bruno Cantarini, Luca |
author_facet | Conticini, Edoardo Sota, Jurgen Falsetti, Paolo Baldi, Caterina Bardelli, Marco Bellisai, Francesca Tosi, Gian Marco Frediani, Bruno Cantarini, Luca |
author_sort | Conticini, Edoardo |
collection | PubMed |
description | INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, few data are available on the role of different imaging techniques in monitoring GCA activity and response to treatment. We report herein a cohort of GCA patients treated with TCZ and followed up with multimodal imaging. Patients and Methods. We collected clinical, laboratory, and imaging data of 11 GCA patients treated with TCZ 162 mg subcutaneously every week. Disease activity was assessed at baseline and within 12 months from the start of treatment using different imaging techniques such as color Doppler ultrasonography (CDUS), magnetic resonance imaging/angiography (MRI/MRA), computed tomography angiography (CTA), and/or positron emission tomography (PET). RESULTS: Four patients were affected by cranial and 7 by LV-GCA. All patients were treated with oral glucocorticoids (GCs) (mean dose 55.68 mg ± 8.19 of prednisone or equivalent) in combination with TCZ. Treatment was preceded in 5 cases by 3 intravenous boluses of 1000 mg methylprednisolone. A significant decrease of the mean dose of oral GCs was observed between baseline and the last follow-up visit (4.65 ± 3.69 mg) (p = 0.003). TCZ treatment significantly decreased erythrocyte sedimentation rate (p < 0.01) and CRP levels (p < 0.01). At follow-up (mean 8.18 ± 3.63 months), all patients were in clinical and serological remission. Moreover, PET, CDUS, MRI/MRA, and CTA did not show any LVV finding. CONCLUSIONS: Our study highlights TCZ efficacy in inducing GCA remission and its steroid-sparing effect. We highlighted a reliability of imaging procedures in the evaluation of disease activity and treatment response. A close disease monitoring with imaging techniques should be taken into account in GCA patients during TCZ treatment. |
format | Online Article Text |
id | pubmed-7537685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-75376852020-10-13 The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis Conticini, Edoardo Sota, Jurgen Falsetti, Paolo Baldi, Caterina Bardelli, Marco Bellisai, Francesca Tosi, Gian Marco Frediani, Bruno Cantarini, Luca Mediators Inflamm Clinical Study INTRODUCTION: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis, mainly affecting elder patients. Monitoring GCA activity during tocilizumab (TCZ) treatment is an unmet need, since low serum levels of C-reactive protein (CRP) during treatment may underestimate disease activity. To date, few data are available on the role of different imaging techniques in monitoring GCA activity and response to treatment. We report herein a cohort of GCA patients treated with TCZ and followed up with multimodal imaging. Patients and Methods. We collected clinical, laboratory, and imaging data of 11 GCA patients treated with TCZ 162 mg subcutaneously every week. Disease activity was assessed at baseline and within 12 months from the start of treatment using different imaging techniques such as color Doppler ultrasonography (CDUS), magnetic resonance imaging/angiography (MRI/MRA), computed tomography angiography (CTA), and/or positron emission tomography (PET). RESULTS: Four patients were affected by cranial and 7 by LV-GCA. All patients were treated with oral glucocorticoids (GCs) (mean dose 55.68 mg ± 8.19 of prednisone or equivalent) in combination with TCZ. Treatment was preceded in 5 cases by 3 intravenous boluses of 1000 mg methylprednisolone. A significant decrease of the mean dose of oral GCs was observed between baseline and the last follow-up visit (4.65 ± 3.69 mg) (p = 0.003). TCZ treatment significantly decreased erythrocyte sedimentation rate (p < 0.01) and CRP levels (p < 0.01). At follow-up (mean 8.18 ± 3.63 months), all patients were in clinical and serological remission. Moreover, PET, CDUS, MRI/MRA, and CTA did not show any LVV finding. CONCLUSIONS: Our study highlights TCZ efficacy in inducing GCA remission and its steroid-sparing effect. We highlighted a reliability of imaging procedures in the evaluation of disease activity and treatment response. A close disease monitoring with imaging techniques should be taken into account in GCA patients during TCZ treatment. Hindawi 2020-09-27 /pmc/articles/PMC7537685/ /pubmed/33061825 http://dx.doi.org/10.1155/2020/3203241 Text en Copyright © 2020 Edoardo Conticini et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Conticini, Edoardo Sota, Jurgen Falsetti, Paolo Baldi, Caterina Bardelli, Marco Bellisai, Francesca Tosi, Gian Marco Frediani, Bruno Cantarini, Luca The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title | The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title_full | The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title_fullStr | The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title_full_unstemmed | The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title_short | The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis |
title_sort | role of multimodality imaging in monitoring disease activity and therapeutic response to tocilizumab in giant cell arteritis |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537685/ https://www.ncbi.nlm.nih.gov/pubmed/33061825 http://dx.doi.org/10.1155/2020/3203241 |
work_keys_str_mv | AT conticiniedoardo theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT sotajurgen theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT falsettipaolo theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT baldicaterina theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT bardellimarco theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT bellisaifrancesca theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT tosigianmarco theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT fredianibruno theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT cantariniluca theroleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT conticiniedoardo roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT sotajurgen roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT falsettipaolo roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT baldicaterina roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT bardellimarco roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT bellisaifrancesca roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT tosigianmarco roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT fredianibruno roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis AT cantariniluca roleofmultimodalityimaginginmonitoringdiseaseactivityandtherapeuticresponsetotocilizumabingiantcellarteritis |